Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
HYPAQUE-M,90% vs IOPAMIDOL-250 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Renal: >95% unchanged; biliary/fecal: <5%
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent